Eli Lilly Stock Earnings Reports

Eli Lilly reported a strong Q1 2026: revenue rose 56% year-over-year driven by Mounjaro (tirzepatide), Zepbound/semaglutide, and momentum across immunology, oncology and neuroscience. Major commercial milestone: FDA approval and U.S. launch of oral GLP-1 orforgopron (brand Foundayo) for obesity, with global regulatory reviews in 40+ countries and a planned U.S. type 2 diabetes submission in Q2. Foundayo launch priorities include payer access (including Medicare bridge program), HCP education, consumer awareness and broad pharmacy/telehealth distribution; early launch metrics are encouraging (thousands of prescribers and ~20,000 patients treated early). R&D updates: multiple positive Phase III readouts across areas — notably ACHIEVE I showing cardiovascular safety (and lower all-cause death signal) for Foundayo vs insulin glargine, positive retatrutide Phase III (TRANSCEND P2D-1) with substantial A1c reductions and large weight loss, and several oncology and immunology trial successes. Lilly announced multiple BD deals/acquisitions to expand pipeline (Orna, Syntessa, Colonia, Ajax, Contessa, Ventix). Financials: Q1 non-GAAP EPS $8.55 (vs $3.34 prior year), gross margin ~82.6%, R&D and SG&A increasing as investments continue, $1.5B dividends and $2.4B share repurchases. 2026 guidance raised: revenue range increased by $2B to $82–85B, non-GAAP EPS guidance raised to $35.50–$37. Key strategic themes: scaling obesity treatments through multiple modalities (injectables, oral, next-gen agonists), leveraging direct-to-consumer/telehealth and employer programs to expand access, and continuing disciplined BD to fill the pipeline.